Created by @DCharabaty •Join us for #IBD #IBDPoll & convo or #Back2Basics MON ~5pmET • #PatientExperience WED • #IBDAlgorithm THUR • Opinions≠med advice 🆓#CME
IBDland on Twittersphere
- Tweets 8,005
- Following 859
- Followers 9,776
- Likes 14,107
Pinned Tweet
Don’t miss this 🧵 on anti-TL1A for #IBD #UC #Crohns!
We review the available data of the 3️⃣ upcoming agents for this 🆕 exciting MOA ! @DCharabaty @vipuljairath 👇🏽👇🏽👇🏽
1/ #MondayNightIBD #Back2Basics
TL1A , a 🆕🎯for inflammation & ?fibrosis
3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns
⚙️MOA, efficacy, safety
🆓CME 👉🏼mnibd.short.gy/TL1AsTW
Support by an educational grant @Sanofi
📍Where are you in your career?
6
9
1,609
#MondayNightIBD retweeted
1/ #MondayNightIBD #Back2Basics
TL1A , a 🆕🎯for inflammation & ?fibrosis
3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns
⚙️MOA, efficacy, safety
🆓CME 👉🏼mnibd.short.gy/TL1AsTW
Support by an educational grant @Sanofi
📍Where are you in your career?
59%
IBD Specialist
11%
General GI, CRsurgery
27%
Trainee, Fellow
3%
PharmD, APP, RN
37 votes • Final results
1
5
4
2,256
#MondayNightIBD retweeted
2/ #MondayNightIBD
🚧~40% mod-sev #IBD have no or LoR to current Rx
🎯TL1A: TNF superfamily member, binds DR3 on T cells, NK cells & ILCs
🥊Drives inflammation (Th1/Th17/Th2) AND fibrosis (fibroblast activation)
🥊anti-TL1A block TL1A–DR3 →⬇️innate + adaptive immunity
1
10
17
1,297
#MondayNightIBD retweeted
3/#MondayNightIBD
🎬Starting w #Duvakitug
🔥Hot off the press
🩺RELIEVE UCCD: Ph2b basket trial:
Parallel UC+CD cohorts (~120 pts each)
💉1 Loading dose DUVA SC→DUVA SC 450mg Q2W vs 900mg Q2W vs PBO
🎯Primary end points @ Wk14
UC: Clin remission
CD: Endo response
1
10
11
1,112
#MondayNightIBD retweeted
4/#MondayNightIBD
RELIEVE-UCCD📊Wk14 outcomes in UC
Bayesian trial→posterior probability(PP)
✅Clin remission(mMS)
48%(900mg)/ 36%(450mg) DUVA vs 20% PBO
Δ26% PP >0.99 | Δ15% PP 0.95
✅Endo Improvemt(MES 0/1)
50%(900mg)/ 45%(450mg) DUVA vs 23% PBO
Δ26% PP >0.99 | Δ21% PP 0.99
1
7
11
2,756
#MondayNightIBD retweeted
5/#MondayNightIBD
RELIEVE UCCD 📊Wk 14 outcomes in #Crohns
🔦Endo Response (≥50% ↓ SES-CD)
48% (900mg)/ 26% (450mg) DUVA vs 13% PBO
Δ33% PP >0.99 | Δ13% PP 0.94
🩺Clinical Remission (PRO2)
37%/37% DUVA vs 26% PBO
Δ10% PP 0.87 (both doses)
1
9
12
3,448
#MondayNightIBD retweeted
6/#MondayNightIBD
RELIEVE-UCCD LTE 🗞️ release (to be presented at upcoming meeting)
🔀Wk14 responders re-randomized to DUVA 900mg or 450mg SC Q4W to wk44
🎯Wk 44- UC clin remission (mMS)
900 mg: 58%
450 mg: 47%
🎯Wk 44- CD endo response (SES-CD)
900 mg: 55%
450 mg: 41%
1
6
6
792
#MondayNightIBD retweeted
7/ DUVA safety (RELIEVE UCCD Wk14)
🚫No⬆️ TEAE signal DUVA vs PBO
🚫No dose-dependent signal
🚫No deaths, CA, MACE, VTE
🧬ADAs low; no neutralizing antibodies
⚠️1 anaphylactic rxn (450mg CD); resolved
📌10 SAEs in 450mg CD arm in 1pt w/ severe COVID, judged unrelated to DUVA
2
9
16
1,101
#MondayNightIBD retweeted
8/ #MondayNightIBD
🎬Next: Tulisokibart
Phase2️⃣trials
🏹ARTEMIS-UC (UC)
🎻APOLLO-CD (CD)
💉TULI 1,000mg IV wk0, then 500mg IV wk 2, 6, 10
OLE: Wk12 responders: 🔀randomized 250 or 100mg IV Tuli Q4W
1
9
11
1,082
#MondayNightIBD retweeted
9/#MondayNightIBD
🏹ARTEMIS-UC 📊Week 12 outcomes
✅Clin remission: 26% TULI vs 1.5% PBO (Δ +25%, p<0.001)
✅Endoscopic improvement: 37% TULI vs 6% PBO (Δ +31%, p<0.001)
1
7
8
932
#MondayNightIBD retweeted
10/#MondayNightIBD
ARTEMIS-UC OLE
OLE study:
TULI Wk 12 responders 🔀 250 vs 100mg IV TULI Q4W
Outcomes at Wk50:
🩺Clinical remission: 48%/32%
🔦Endo response: 48%/36%
🆑Disease clearance (symptomatic+mucosal remission): 44%/32%
1
7
6
767
#MondayNightIBD retweeted
11/ #MondayNightIBD
🎻APOLLO-CD
📊TULI Week 12 outcomes
✅ Clin remission (CDAI <150): 49% (27/55)
✅Endo response (≥50% ↓ SES-CD): 26% (13/50)
⏳OLE: Wk 12 responders 🔀IV 250mg or 100 mg Q4W
At week 50
💎Clinical remission: 56%/42%
💎Endo response 28%/16%
1
5
8
747
#MondayNightIBD retweeted
12/ TULI safety (ARTEMIS-UC + APOLLO-CD)
🚫No ⬆️AEs signals Tuli vs PBO
🚫No deaths, infusion rxns, serious infections
🧬ADAs low, no impact on efficacy
⚠️1 Bowen's disease — related per investigator, unrelated per sponsor
1
4
8
776
#MondayNightIBD retweeted
13/ 🎬Finally, Afimkibart
🌻TUSCANY-2 (Ph2b, UC) RCT
💉Induction AFIM SC 50/150/450mg Q4W through Wk 14 vs PBO
→Treat through to wk56 w one of 3 AFIM doses Q4W
🎯Primary endpt: clinical remission tMS 2 or less
*Afim Ph2 data is UC-only; no CD trial data reported yet
1
4
8
866
#MondayNightIBD retweeted
14/ #MondayNightIBD
TUSCANY-2: Wk14 induction AFIM in UC
🩺Clin Rem by mMS:
450 mg: 32% (Δ +20% vs PBO)
150 mg: 35% (Δ +23%)
50 mg: 30% (Δ +18%)
PBO: 12%
⚠️Endpoint did not reach statistical significance per tMS, but meaningful improvemt by mMS & ⬇️ in FCP across all doses
1
5
7
844
#MondayNightIBD retweeted
15/#MondayNightIBD
TUSCANY-2 Wk 14 endo outcomes AFIM in UC:
🔦Endo improvement:
450mg 41%
150 mg 38%
50mg 40%
vs PBO 19%
Δ ~20 pp across all doses
1
4
9
738
#MondayNightIBD retweeted
16/ #MondayNightIBD
TUSCANY-2 in UC wk56 data:
Same-dose clinical remission (mMS) from wk 14 to wk56
450mg: 29% →36%
150mg: 38% → 39%
50mg: 30% → 31%
🩺Remission was sustained across all doses w modest gain at highest dose
1
4
5
761
#MondayNightIBD retweeted
17/ #MondayNightIBD
AFIM safety
🚫no ⬆️TEAEs signal Afim vs PBO at all doses
🚫No deaths
🚫No new signals
📌Common AEs (≥5%): nausea, UTI, UC flare, anemia, fatigue, headache, pyrexia
1
3
4
673
#MondayNightIBD retweeted
18/ #MondayNightIBD
🔥Anti-TL1A-Exciting 🆕 MOA
🧘🏽♀️RELIEVE-UCCD/DUVA
🏹ARTEMIS-UC & 🎻APPOLO-CD/TULI
🌻TUSCANY(UC)/AFIM
✅Meaningful induction efficacy
✅Efficacy maintained at 1yr
✅👌🏽 Safety, no class 🚩
✅Low immunogenicity
💬What are you mostly excited about for this MOA?
1
8
17
3,826
#MondayNightIBD retweeted
19/ #MondayNightIBD
#PostB2B #IBDPoll 1️⃣
🆓#CME👉🏼 mnibd.short.gy/TL1AsTWpost
🧩TNF-like cytokine 1A (TL1A) bind to which receptor to drive inflammation (& fibrosis) in the gut?
(😉 check tweet 2 of this 🧵)
0%
IL-23R
54%
Death Receptor DR3
39%
TNF-R1
7%
α4β7 integrin
28 votes • Final results
1
3
3
727